Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acimtamig - Affimed Therapeutics

Drug Profile

Acimtamig - Affimed Therapeutics

Alternative Names: AFM-13; Anti-CD30 anti-CD16A antibody - Affimed Therapeutics; CD30/CD16A; CD30/CD16A ICE®; TandAb AFM13

Latest Information Update: 17 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Hodgkin's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma
  • Phase I/II Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Jun 2024 Efficacy and adverse events data from phase II clinical trials in Hodgkin's disease released by Affimed
  • 11 Jan 2024 Affimed Therapeutics completes the phase II REDIRECT trial in Peripheral t-cell lymphoma and Mycosis fungoides (Second-line therapy or greater) in USA, Spain, Australia, France, Germany, Italy, South Korea, Poland, Russian and Turkey (NCT04101331) (EudraCT2019-001003-20)
  • 11 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Hodgkin lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top